Strand Diagnostics LLC, maker of the know error system, named Laura Beggrow its new president. Strand Diagnostics recruited her to drive the sales and marketing efforts of the company.

Prior to joining Strand Diagnostics, Beggrow served as VP of US sales and marketing at Genomic Health. During her tenure, she was responsible for commercializing the company’s Oncotype DX products in the breast and colon cancer markets, growing sales of the Oncotype DX test from $10 million to more than $200 million per year.

The know error system compares the DNA profile of a biopsy specimen to the DNA profile of a reference sample taken via cheek swab. This process safeguards patients from diagnostic and treatment errors that may occur due to undetected switches or contamination of biopsy specimens during the complex diagnostic testing cycle for cancer.